#China #Hong Kong #Ascletis #EASD #ASC36_35 FDC

Ascletis Unveils Groundbreaking Preclinical Data on ASC36_35 FDC

In a significant breakthrough for obesity treatment, Ascletis Pharma Inc. announced compelling preclinical data for its investigational drug, ASC36_35 FDC, during the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting. The event, which is taking place in Milan, Italy, serves as a prominent platform for discussing advancements in diabetes research and treatment options.

Understanding ASC36_35 FDC

ASC36_35 FDC is a novel co-formulation combining ASC36, a peptide amylin receptor agonist, and ASC35, a dual GLP-1 receptor/GIP receptor agonist. This combination is designed as a self-administered, once-monthly subcutaneous injection aimed particularly at patients struggling with obesity. The innovative formulation utilizes Ascletis' proprietary Ultra-Long-Acting Platform (ULAP) technology, which enhances the drug's effectiveness and reduces administration frequency.

Preclinical Results Highlight Weight Loss Potential

The preclinical data presented by Ascletis indicates that ASC36_35 FDC produced superior weight loss compared to the combination of eloralintide and tirzepatide in a diet-induced obese (DIO) animal model. This finding is particularly promising, as the DIO model is a widely accepted method for simulating obesity-related metabolic disorders. According to Dr. Jinzi Jason Wu, Founder and CEO of Ascletis, the results suggest that the combined effects of ASC36 and ASC35 may provide a greater weight loss benefit than existing treatment modalities.

Event Details and Future Implications

The specific presentation for this innovative research is scheduled for October 1, 2026, at the EASD Annual Meeting. As part of a short oral discussion session, the research aims to foster dialogue among leading researchers and healthcare professionals about advancing treatment options for obesity. Dr. Wu emphasized the importance of developing effective medications for managing obesity, a significant health concern affecting millions globally.

Ascletis' Commitment to Innovation

Founded in 2013 and publicly listed on the Hong Kong Stock Exchange as HKEX 1672, Ascletis Pharma has established itself as a leader in biotechnology, focusing on the development and commercialization of treatments for metabolic diseases. Utilizing cutting-edge technologies like Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), the company is dedicated to pioneering drugs that can transform patient care.

As the global healthcare community accelerates efforts to tackle the obesity epidemic, the promising results of ASC36_35 FDC offer a beacon of hope for effective obesity management. With the ongoing advancements in obesity treatments, the potential of ASC36_35 FDC may soon become a reality for those in need of innovative therapeutic options.

With discussions at EASD poised to attract significant attention, stakeholders eagerly await the complete data release and understanding of the implications of these findings on future obesity therapies.